Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

Theratechnologies Inc (TSX: TH )

2.700 +0.040 (+1.50%)
Streaming Delayed Price Updated: 12:52 PM EST, Feb 20, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Theratechnologies Inc

< Previous 1 2 3 Next >
Theratechnologies Announces All U.S. Oncology Clinical Sites Now Enrolling for Phase 1 Trial of Sudocetaxel Zendusortide
From Theratechnologies
Via GlobeNewswire
Theratechnologies Completes 1-for-4 Reverse Stock Split
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Amendments to its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces 1-for-4 Reverse Stock Split
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Second Quarter 2023 Financial Results and Business Updates
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Second Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Draws Down on US$20 Million Second Tranche Under its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Theratechnologies June 13 Oncology Investigator Call to Update Investors & Analysts on Phase 1 Sudocetaxel Zendusortide Trial
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives FDA Agreement to Amended Trial Protocol for its Lead PDC Candidate Sudocetaxel Zendusortide
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preliminary Safety and Efficacy Data from Phase 1 Trial of Sudocetaxel Zendusortide in Heavily Pretreated Cancer Patients at ASCO 2023
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports on its Annual Meeting of Shareholders
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Trogarzo® (Ibalizumab-uiyk) Shortens Time to HIV Undetectability and Extends Durability of Undetectability and Viral Suppression in a Matched Treatment Comparison
From Theratechnologies
Via GlobeNewswire
Theratechnologies Data Presentations at AACR 2023 Showcase Potential of Sudocetaxel Zendusortide as a Single Agent and in Combination with other Anticancer Therapies
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Business Updates for First Quarter 2023
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce First Quarter 2023 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Present Preclinical Data at AACR Demonstrating Synergy Between TH1902 and Anti-PD-L1 Immunotherapy in Cold Tumor Model
From Theratechnologies
Via GlobeNewswire
Theratechnologies Receives Nasdaq Notification Letter Regarding Share Price
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results and Business Updates for the Fourth Quarter and Full Year Fiscal 2022
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Amendment to its Term Loan Facility With Affiliates of Marathon Asset Management
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents New Tesamorelin Data Demonstrating Improvement of Metabolic Syndrome in People with HIV
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Path to Resume TH1902 Clinical Development
From Theratechnologies
Via GlobeNewswire
Theratechnologies to Announce Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update
From Theratechnologies
Via GlobeNewswire
Open Letter to Shareholders from CEO Paul Levesque
Theratechnologies Announces Fiscal Year 2023 Guidance and Operating Plan’s Key Objectives 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Update from Ongoing TH1902 Study
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14,... 
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Data Showing High Expression of Sortilin (SORT1) in Multiple Solid Tumors from Tissue Microarrays
From Theratechnologies
Via GlobeNewswire
Theratechnologies Reports Financial Results for the Third Quarter of Fiscal 2022 and Provides Business Update
From Theratechnologies
Via GlobeNewswire
Theratechnologies Presents Data Demonstrating High Expression of Sortilin (SORT1) in Multiple Tumor Types at 34th EORTC-NCI-AACR Symposium
From Theratechnologies
Via GlobeNewswire
Theratechnologies’ Trogarzo® Approved by FDA for 30-Second Intravenous (IV) Push, Simplifying HIV Treatment for Heavily Treatment-Experienced Population
From Theratechnologies
Via GlobeNewswire
Theratechnologies Announces Closing of Funding of $40 Million Under the Terms of its Credit Agreement
This news release constitutes a “designated news release” for the purposes of the Company’s prospectus supplement dated December 16, 2021 to its short form base shelf prospectus dated December 14,... 
From Theratechnologies
Via GlobeNewswire
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.